Effect of glycaemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease: A systematic review and meta-analysis - PubMed (original) (raw)
Meta-Analysis
. 2019 Mar;21(3):732-735.
doi: 10.1111/dom.13581. Epub 2018 Dec 18.
Affiliations
- PMID: 30426626
- DOI: 10.1111/dom.13581
Meta-Analysis
Effect of glycaemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease: A systematic review and meta-analysis
Yael Barer et al. Diabetes Obes Metab. 2019 Mar.
Abstract
The role of intensive glucose control in people with type 2 diabetes and pre-existing cardiovascular disease (CVD) is controversial. The aim of this systematic review and meta-analysis was to determine in a subset of people with type 2 diabetes and pre-existing CVD, the CV effect of intensive glucose control versus standard of care. We searched Medline, the Cochrane library, EMBASE and the National Institutes of Health Trial registration database for randomized controlled trials that evaluated the effect of intensive glucose control versus standard glucose control in people with type 2 diabetes on incident CVD. Data were extracted using a structured form. When data were not available in the publications, authors were contacted. Eight trials involving 8339 participants were included. Among adults with type 2 diabetes and pre-existing CVD, there was no difference in the risk of CV events in those allocated to intensive glucose control compared with those in the standard care arm (relative risk 0.98, 95% confidence interval 0.87-1.09). In conclusion, in people with diabetes and pre-existing CVD, intensive glucose control versus standard care had a neutral effect on incident CV events.
Keywords: cardiovascular disease; glucose control; intensive; meta-analysis; systematic review; type 2 diabetes.
© 2018 John Wiley & Sons Ltd.
Similar articles
- Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
Seidu S, Achana FA, Gray LJ, Davies MJ, Khunti K. Seidu S, et al. Diabet Med. 2016 Mar;33(3):280-9. doi: 10.1111/dme.12885. Epub 2015 Sep 8. Diabet Med. 2016. PMID: 26282461 Review. - Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, Wetterslev J. Hemmingsen B, et al. Cochrane Database Syst Rev. 2013 Nov 11;(11):CD008143. doi: 10.1002/14651858.CD008143.pub3. Cochrane Database Syst Rev. 2013. PMID: 24214280 Updated. Review. - The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis.
Marso SP, Kennedy KF, House JA, McGuire DK. Marso SP, et al. Diab Vasc Dis Res. 2010 Apr;7(2):119-30. doi: 10.1177/1479164109353367. Epub 2009 Dec 4. Diab Vasc Dis Res. 2010. PMID: 20382775 Review. - Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials.
Fang HJ, Zhou YH, Tian YJ, Du HY, Sun YX, Zhong LY. Fang HJ, et al. Int J Cardiol. 2016 Sep 1;218:50-58. doi: 10.1016/j.ijcard.2016.04.163. Epub 2016 May 13. Int J Cardiol. 2016. PMID: 27236108
Cited by
- Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice.
Lim LL, Chow E, Chan JCN. Lim LL, et al. Nat Rev Endocrinol. 2023 Mar;19(3):151-163. doi: 10.1038/s41574-022-00776-2. Epub 2022 Nov 29. Nat Rev Endocrinol. 2023. PMID: 36446898 Review. - Predictive Capacity of Beat-to-Beat Blood Pressure Variability for Cardioautonomic and Vascular Dysfunction in Early Metabolic Challenge.
Fares SA, Bakkar NZ, El-Yazbi AF. Fares SA, et al. Front Pharmacol. 2022 Jun 24;13:902582. doi: 10.3389/fphar.2022.902582. eCollection 2022. Front Pharmacol. 2022. PMID: 35814210 Free PMC article. - Association of type 2 diabetes remission and risk of cardiovascular disease in pre-defined subgroups.
Hounkpatin H, Stuart B, Farmer A, Dambha-Miller H. Hounkpatin H, et al. Endocrinol Diabetes Metab. 2021 Jun 19;4(3):e00280. doi: 10.1002/edm2.280. eCollection 2021 Jul. Endocrinol Diabetes Metab. 2021. PMID: 34277996 Free PMC article. - The residual cardiorenal risk in type 2 diabetes.
Giugliano D, Maiorino MI, Bellastella G, Esposito K. Giugliano D, et al. Cardiovasc Diabetol. 2021 Feb 5;20(1):36. doi: 10.1186/s12933-021-01229-2. Cardiovasc Diabetol. 2021. PMID: 33546683 Free PMC article. - Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
Giugliano D, Longo M, Scappaticcio L, Caruso P, Esposito K. Giugliano D, et al. Cardiovasc Diabetol. 2021 Jan 11;20(1):17. doi: 10.1186/s12933-021-01213-w. Cardiovasc Diabetol. 2021. PMID: 33430860 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical